Key clinical point: Vitamin D supplementation may improve headache characteristics and disability levels in patients with episodic migraine, especially among those with aura, possibly through attenuation of calcitonin gene-related peptide level.
Major finding: After 12 weeks, the vitamin D vs placebo group had a significant improvement in mean headache days (4.71 vs 6.43 days/month; P = .031) and mean Migraine Disability Assessment Questionnaire score (21.49 vs 31.16; P = .016).
Study details: A post hoc analysis of a double-blind study which included patients with episodic migraine randomly assigned to receive either vitamin D 2,000 IU/day (n = 40) or placebo (n = 40).
Disclosures: This study was supported by the Tehran University of Medical Sciences & Health Services. The authors reported no competing interests.
Citation: Ghorbani Z et al. J Headache Pain. 2020 Feb 24. doi: 10.1186/s10194-020-01090-w.